A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The prospective participant must meet, at least, all of the criteria below to be eligible for study participation. The participant:
Is a minimum age of 18 years (adults) or 50 years (aging participants);
Is male or female;
Has confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice);
Has commenced antiretroviral treatment with Raltegravir according to the recommendations made in the Summary of Product Characteristics at the time of enrollment on the study, or a maximum 6 months prior to enrollment on the study;
Has any cluster of differentiation (CD4) cell (specialized white blood cell) count upon enrollment on the study.
You may not be if
If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation. The participant:
For which Raltegravir, or its ingredients, are contraindicated;
Has intolerance to Raltegravir, or its ingredients;
If female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation during the study.
Clareo Health | A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
